Characteristics of hematopoietic stem cell transplantation patients
. | Donor → Recipient . | . | |
|---|---|---|---|
. | M → M n = 46, (%) . | F → M n = 75, (%) . | |
| Primary disease | |||
| Acute myeloid leukemia | 9 (20) | 17 (23) | |
| Acute lymphoblastic leukemia | 3 (7) | 8 (11) | |
| Chronic myeloid leukemia | 18 (39) | 19 (25) | |
| Chronic lymphocytic leukemia | 1 (2) | 5 (7) | |
| Myelodysplastic syndrome | 6 (13) | 11 (15) | |
| Non-Hodgkin lymphoma | 4 (9) | 10 (13) | |
| Hodgkin disease | 1 (2) | 2 (3) | |
| Multiple myeloma | 1 (2) | 2 (3) | |
| Other | 3 (7) | 1 (1) | |
| Good prognosis* | |||
| Yes | 23 (50) | 31 (41) | |
| No | 23 (50) | 44 (59) | |
| Patient age | |||
| Median (range), y | 47 (21-70) | 45 (19-66) | |
| Donor age | |||
| Median (range), y | 34 (21-68) | 39 (14-69) | |
| HSC donor | |||
| Unrelated | 20 (44) | 24 (32) | |
| Related | 26 (56) | 51 (68) | |
| HSC source | |||
| Bone marrow | 24 (52) | 44 (59) | |
| Peripheral blood stem cells | 22 (48) | 31 (41) | |
| HSC processing | |||
| Unmanipulated | 31 (67) | 60 (80) | |
| T-cell depleted† | 15 (33) | 15 (20) | |
| Conditioning regimen | |||
| Myeloablative | 32 (70) | 53 (71) | |
| Nonmyeloablative | 14 (30) | 22 (29) | |
| Total samples tested | 115 | 368 | |
| Pretransplantation samples | 10 | 31 | |
| Collected day 0-180 | 32 | 54 | |
| Collected after day 180 | 73 | 283 | |
| Median samples/patient (range) | 2 (1-6) | 4 (1-21) | |
| Days after HSCT that the last sample was collected | |||
| Median (range), days | 505 (180-3881) | 428 (180-3249) | |
. | Donor → Recipient . | . | |
|---|---|---|---|
. | M → M n = 46, (%) . | F → M n = 75, (%) . | |
| Primary disease | |||
| Acute myeloid leukemia | 9 (20) | 17 (23) | |
| Acute lymphoblastic leukemia | 3 (7) | 8 (11) | |
| Chronic myeloid leukemia | 18 (39) | 19 (25) | |
| Chronic lymphocytic leukemia | 1 (2) | 5 (7) | |
| Myelodysplastic syndrome | 6 (13) | 11 (15) | |
| Non-Hodgkin lymphoma | 4 (9) | 10 (13) | |
| Hodgkin disease | 1 (2) | 2 (3) | |
| Multiple myeloma | 1 (2) | 2 (3) | |
| Other | 3 (7) | 1 (1) | |
| Good prognosis* | |||
| Yes | 23 (50) | 31 (41) | |
| No | 23 (50) | 44 (59) | |
| Patient age | |||
| Median (range), y | 47 (21-70) | 45 (19-66) | |
| Donor age | |||
| Median (range), y | 34 (21-68) | 39 (14-69) | |
| HSC donor | |||
| Unrelated | 20 (44) | 24 (32) | |
| Related | 26 (56) | 51 (68) | |
| HSC source | |||
| Bone marrow | 24 (52) | 44 (59) | |
| Peripheral blood stem cells | 22 (48) | 31 (41) | |
| HSC processing | |||
| Unmanipulated | 31 (67) | 60 (80) | |
| T-cell depleted† | 15 (33) | 15 (20) | |
| Conditioning regimen | |||
| Myeloablative | 32 (70) | 53 (71) | |
| Nonmyeloablative | 14 (30) | 22 (29) | |
| Total samples tested | 115 | 368 | |
| Pretransplantation samples | 10 | 31 | |
| Collected day 0-180 | 32 | 54 | |
| Collected after day 180 | 73 | 283 | |
| Median samples/patient (range) | 2 (1-6) | 4 (1-21) | |
| Days after HSCT that the last sample was collected | |||
| Median (range), days | 505 (180-3881) | 428 (180-3249) | |